DETAILED ACTION
Notice of Pre-AIA or AIA Status
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
2. Applicant’s election without traverse of Group II (methods), and species of ECG, transtuzumab, CHO cell and HER2, in the replies filed on June 6, 2025 and July 23, 2026 is acknowledged.
3. Claim 19 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter. Election was made without traverse in the replies filed on June 6, 2025 and July 23, 2026.
4. Examination followed guidelines provided by MPEP 803.02. The elected species appeared to be novel and nonobvious over the prior art. Therefore, the search and examination was extended. Prior art was found that anticipates nonelected species. The Markush claims were rejected and claims to nonelected species were withdrawn from further consideration. The claims were searched to the extent of the elected species and the nonelected species shown below.
Information Disclosure Statement
5. The information disclosure statements (dated April 28, 2022 and January 19, 2023 and July 24, 2024) were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The statements were considered. Signed copies of form 1449 are enclosed herewith.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
6. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Niu et al. The reference has a date of 2004 which antedates the present claims having an effective filing date of March 16, 2020 and priority claim to application dated 2019. The reference teaches the inhibition of fucosyltransferase by gallic acid and derivatives such as ECGC. See abstract, page 53.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
7. Claim(s) 2-6, 13-18 and 20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Niu et al. in view of Beuger et al. (US 20110151513).
Determining the scope and contents of the prior art
Niu et al. teaches the inhibition of fucosyltransferase by gallic acid and derivatives, for example, ECGC.
The reference suggests the inhibition of fucosyltransferase inside a cell and in vivo. For example page 51, page 55, column 2. Relevant to claim 2.
“At a cellular level they have been shown to inhibit cell adhesion, induce apoptosis of tumor cells...”
“This finding could help to further our understanding of many in vivo effects of these compounds...”
Beuger et al. teaches the inhibition of fucosyltransferase in mammalian cells, including, CHO cells. For example, paragraph [0031]. Relevant to claim 20.
The limitations recited in claims 3-6, 13-18 are inherent to the structure and activity of the inhibitor of fucosyltransferase.
Ascertaining the differences between the prior art and the claims at issue
The difference between Niu et al. and the present claims are the limitations of claims 2-6, 13-18 and 20 are not explicitly taught. Moreover, the difference is the application of the inhibition of fucosytransferase inhibition specifically to CHO cells.
Resolving the level of ordinary skill in the pertinent art - considering objective evidence present in the application indicating obviousness
The skilled artisan has the teaching and suggestion to practice the presently claimed methods. The motivation is to apply the explicit teaching to a pharmacological setting, such as in a cell or in vivo. The skilled artisan has a reasonable expectation of success in practicing the invention in the present claims. For these reasons, the claims are found to be prima facie obvious over the prior art.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUN JAE YOO/Primary Examiner, Art Unit 1621